SEARCH

SEARCH BY CITATION

References

  • 1
    Pickering TG. 24 hour ambulatory blood pressure monitoring: Is it necessary to establish a diagnosis before instituting treatment of hypertension? J Clin Hypertens (Greenwich). 1999;1(1):3340.
  • 2
    Cushman WC, Black HR. Hypertension in older persons. J Clin Hypertens (Greenwich). 1999;1(1):5561.
  • 3
    Miller ER Jr, Erlinger TP, Young DR, et al. Lifestyle changes that reduce blood pressure: implementation in clinical practice. J Clin Hypertens (Greenwich). 1999;1(3):191198.
  • 4
    Moser M. Lifestyle interventions: they lower blood pressure: can we make them work? J Clin Hypertens (Greenwich). 1999;1:170172.
  • 5
    Gifford RW Jr. A missed opportunity: our failure to control hypertension optimally. J Clin Hypertens (Greenwich). 2000;2(1):2124.
  • 6
    Setaro JF. An update on the diagnostic evaluation of the hypertensive patient. J Clin Hypertens (Greenwich). 2000;2(1):2532.
  • 7
    Ferdinand KC. Substance abuse and hypertension. J Clin Hypertens (Greenwich). 2000;2(1):3740.
  • 8
    Nemade SS, Ciocon JO. Blood pressure therapy in the elderly: an observation in octogenarians. J Clin Hypertens (Greenwich). 2000;2(4):263272.
  • 9
    Moser M. Treatment of hypertension in the very elderly: a clinician's point of view. J Clin Hypertens (Greenwich). 2003;5(5):310312.
  • 10
    Basile J. Hypertension in the elderly: a review of the importance of systolic blood pressure elevation. J Clin Hypertens (Greenwich). 2002;4(2):108112.
  • 11
    Moser M. More on isolated systolic hypertension, diabetes, nephropathy and hypertension, and use of low-sodium diets in obese hypertensives. J Clin Hypertens (Greenwich). 2002;4(2):8990.
  • 12
    Moser M, Giles T, Oparil S. Conflicting and confusing data from the hypertension treatment trials: whom and what should you believe? J Clin Hypertens (Greenwich). 2005;7(7):403408.
  • 13
    Giles TD. Blood pressure: the better biomarker: delay in clinical application. J Clin Hypertens (Greenwich). 2007;9(12):918920.
  • 14
    Appel LJ. At the tipping point: accomplishing population-wide sodium reduction in the United States. J Clin Hypertens (Greenwich). 2008;10(1):711.
  • 15
    Viera AJ, Kshirsagar AV, Hinderliter AL. Lifestyle modifications to lower or control high blood pressure: is advice associated with action? The Behavioral Risk Factor Surveillance Survey. J Clin Hypertens (Greenwich). 2008;10(2):105111.
  • 16
    Moser M, Franklin SS. Hypertension management: results of a new national survey for the Hypertension Education Foundation: Harris Interactive. J Clin Hypertens (Greenwich). 2007;9(5):316323.
  • 17
    Moser M, Cushman WC, Ziegler MG. The treatment of hypertension in the elderly. J Clin Hypertens (Greenwich). 2008;10(1):5868.
  • 18
    Moser M, Guyther JR, Finnerty F, et al. Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 1977;237:255.
  • 19
    Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003;289:25602572.
  • 20
    Lewington S, Clarke R, Qizilbash N, et al; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:19031913.
  • 21
    Moser M, Giles TD, Izzo JL, et al. Prehypertension: what is it and should it be treated? J Clin Hypertens (Greenwich). 2006;8(11):812818.
  • 22
    Smith McF. Mild hypertension: to treat or not to treat. Ann N Y Acad Sci. 1978;304:466.
  • 23
    Neaton JD, Grimm RH Jr, Prineas RJ, et al. Treatment of Mild Hypertension Study: final results. Treatment of Mild Hypertension Study Research Group. JAMA. 1993;270(6):713724.
  • 24
    Julius S, Nesbitt SD, Egan BM, et al; Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl Med. 2006;354(16):16851697.
  • 25
    The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. (ALLHAT). JAMA. 2002;288(23):29812997.
  • 26
    Moser M. Results of ALLHAT: Is this the final answer regarding initial antihypertensive drug therapy? Arch Intern Med. 2003;163:12691273.
  • 27
    Moser M, Oparil S, Cushman W, et al. The ALLHAT study revisited: do newer data from this trial and others indicate changes in treatment guidelines? J Clin Hypertens (Greenwich). 2007;9(5):372380.
  • 28
    Moser M, Pickering TG, Weber MD. Roundtable discussion: blood pressure lowering by any means, or do specific medications make a difference? J Clin Hypertens (Greenwich). 2001;3(6):369375.
  • 29
    Dahlof B, Sever PS, Poulter NR, et al; ASCOT Investigators. The Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet. 2005;366:895906.
  • 30
    Julius S, Kjeldsen S, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet. 2004;363:20222031.
  • 31
    Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of differenct blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet. 2003;362:15271535.
  • 32
    Dahlof B, Devereux RB, Kjedlsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (Life). Lancet. 2002;359:9951003.
  • 33
    MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: Principal results in older patients. BMJ. 1992;304:405412.
  • 34
    Mancia G, De Backer G, Dominiczak A, et al. 2007. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):11051187.
  • 35
    Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366:15451553.
  • 36
    Moser M, Pickering TG, Cushman WC. The role of B-blockers in the management of hypertension. J Clin Hypertens (Greenwich). 2005;7(5):295299.
  • 37
    PROGRESS Collaborative Study Group. Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:10331041.
  • 38
    Moser M. New-onset diabetes in the hypertension treatment trials: a point of view. J Clin Hypertens (Greenwich). 2004;6(11):610613.
  • 39
    Moser M, Sowers JR, Oparil S, et al. New-onset diabetes in treated hypertensive patients: is it clinically significant? J Clin Hypertens (Greenwich). 2005;7(2):9095.
  • 40
    Gurwitz JH, Bohn RL, Glynn RJ, et al. Antihypertensive drug therapy and the initiation of treatment for diabetes mellitus. Ann Intern Med. 1993;118:273278.
  • 41
    Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med. 2000;342:905912.
  • 42
    Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 2004;43:963969.
  • 43
    Franklin SS. The special problem of isolated systolic hypertension. In: BlackHR, ElliottWJ, eds. Hypertension: A Companion to Braunwald's Heart Disease. Philadelphia, PA: Elsevier Saunders; . 2007:169177.
  • 44
    Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339:19571963.
  • 45
    Moser M, Cushman W, Handler J. Resistant or difficult-to-treat hypertension. J Clin Hypertens (Greenwich). 2006;8(6):434440.
  • 46
    Rosendorff C, Black HR, Cannon CP, et al; American Heart Association Council for High Blood Pressure Research; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Epidemiology and Prevention. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115(21):27612788.
  • 47
    Moser M, Macaulay AI. Medical therapy of hypertension. 3. Results of long-term treatment with presently available drugs. N Y State J Med. 1960;60:26792688.
  • 48
    Moser M, Black HR. The role of combination therapy in the management of hypertension. Am J Hypertens. 1998;11:73s78s.
  • 49
    Moser M, Pickering T, Sowers JR. Combination drug therapy in the management of hypertension: when, with what, and how? J Clin Hypertens (Greenwich). 2000;2(2):9498.
  • 50
    Moser M. Combination therapy for hypertension: an update. J Clin Hypertens (Greenwich). 2003;5(4):247248.
  • 51
    Weiss RJ, Weber MA, Carr AA, et al. A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel B-blocker, in patients with mild to moderate hypertension. J Clin Hypertens (Greenwich). 2007;9(9):667676.
  • 52
    Moser M, Izzo JL, Sica DA. The use of renin inhibitors in the management of hypertension. J Clin Hypertens (Greenwich). 2007;9(9):701770.
  • 53
    Shepherd AM. New and investigational drugs for hypertension. In: BlackHR, ElliottWJ, eds. Hypertension: A Companion to Braunwald's Heart Disease. Philadelphia, PA: Elsevier Saunders; . 2007:295302.
  • 54
    Black HR, Bakris GL, Weber MA, et al. Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich). 2007;9(10):760769.
  • 55
    Moser M. Concerns abut authorship and bias in scientific publications. J Clin Hypertens (Greenwich). 2006;8(9):613614.
  • 56
    Moser M. Medical education and the management of hypertension. J Clin Hypertens (Greenwich). 2002;4(3):162163.
  • 57
    Handler J. The newly identified hypertensive patient: cost-effective laboratory investigation. J Clin Hypertens (Greenwich). 2008;10(1):7780.
  • 58
    Moser M. Hypertension treatment: a success story. J Clin Hypertens (Greenwich). 2006;8(5):313314.
  • 59
    Moser M, Hebert P. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in the hypertension treatment trials. J Am Coll Cardiol. 1996;27(5):12141218.